TP53 and ovarian carcinoma: The WEE1 inhibitor adavosertib disrupts the G2/M checkpoint, promoting apoptosis in DNA-damaged cancer cells, and has demonstrated efficacy in recurrent TP53-mutant ovarian cancer (137).